Primary prevention of cardiovascular disease: Cost-effectiveness comparison

International Journal of Technology Assessment in Health Care

Volumn 23, Issue 1, 2007, Pages 71-79

  Franco, Oscar H ^a,b   Der Kinderen, Arno J ^a,c   De Laet, Chris ^d   Peeters, Anna ^e   Bonneux, Luc ^f  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNILEVER RESEARCH   (United Kingdom)

^c Department of Business Economics St Alatus ^*  (Netherlands)

^d BELGIAN HEALTH CARE KNOWLEDGE CENTRE KCE   (Belgium)

^e MONASH UNIVERSITY   (Australia)

^f NETHERLANDS INTERDISCIPLINARY DEMOGRAPHIC INSTITUTE   (Netherlands)

Author keywords

Cardiovascular disease; Cost effectiveness analysis; Primary prevention

Indexed keywords

COST EFFECTIVENESS; DISEASES; DRUG PRODUCTS; MATHEMATICAL MODELS; RISK ASSESSMENT;

CARDIOVASCULAR DISEASES; COST-EFFECTIVENESS ANALYSIS; PRIMARY PREVENTION;

CARDIOVASCULAR SYSTEM;

ACETYLSALICYLIC ACID; AMFEBUTAMONE; ANTIHYPERTENSIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DISEASE SEVERITY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; RISK REDUCTION; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT OUTCOME;

ADULT; AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PRIMARY PREVENTION;

EID: 34247525221     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462307051598     Document Type: Article

References (33)

1. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991;121:293-298.
2. College, Tarieven, Gezondheidszorg. Available at: www.ctgzorg.nl. Accessed 2004.
3. College voor zorgverzekeringen. Farmacotherapeutisch Kompas: medisch farmaceuthische voorlichting/uitgave van de Commissie Farmaceuthische hulp van het College voor zorgverzerkeringen. Amstelveen: College voor zorgverzekeringen; 2003.
4. Committee SMA. Standing Medical Advisory Committee. the use of statins. 1997 (11061 HCD Aug 97 [04]). London: Department of Health.
5. Dawber TR, Meadors GF, Moore FE Jr. Epidemiological approaches to heart disease: The Framingham Study. Am J Public Health. 1951;41:279-281.
6. Drummond M, Brandt A, Luce B, Rovira J. Standardizing methodologies for economic evaluation in health care. Practice, problems, and potential. Int J Technol Assess Health Care. 1993;9:26-36.
7. Euro-medicines. Available at: www.euromedicines.org. Accessed 2001.
8. Franco OH, Peeters A, Looman CW, Bonneux L. Cost effectiveness of statins in coronary heart disease. J Epidemiol Community Health. 2005;59:927-933.
9. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: A summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;136:161-172.
10. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA. 1997;278:313-321.
11. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability in the elderly: The Rotterdam Elderly Study. Eur J Epidemiol. 1991;7:403-422.
12. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2003;CD000031.
13. Hunink MGM GP, Siegel JE, et al. Decision making in health and medicine: Interpreting evidence and values. Cambridge, England: Cambridge University Press; 2001.
14. Jacobson TA. Clinical context: Current concepts of coronary heart disease management. Am J Med. 2001;110(Suppl 6A):3S-11S.
15. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol. 1979;110:281-290.
16. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology. 2001;120:594-606.
17. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials. JAMA. 1999;282:2340-2346.
18. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J. 1992;146:473-481.
19. Law MR, Wald NJ. Risk factor thresholds: Their existence under scrutiny. BMJ. 2002;324:1570-1576.
20. Lightwood JM, Glantz SA. Short-term economic and health benefits of smoking cessation: Myocardial infarction and stroke. Circulation. 1997;96:1089-1096.
21. Malik IS, Bhatia VK, Kooner JS. Cost effectiveness of ramipril treatment for cardiovascular risk reduction. Heart. 2001;85:539-543.
22. Marshall T. Coronary heart disease prevention: Insights from modelling incremental cost effectiveness. BMJ. 2003;327:1264.
23. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2000;356:1955-1964.
24. Parrott S, Godfrey C. Economics of smoking cessation. BMJ. 2004;328:947-949.
25. Pharoah PD, Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: Life table method applied to health authority population. BMJ. 1996;312:1443-1448.
26. Report HIC. Dutch guidelines for pharmacoeconomic research. Available at: www.ispor.org/PEguidelines/source/ PE_guidelines_english_Netherlands.pdf. Accessed 1999.
27. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307.
28. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2002;CD000146.
29. Statistikbank HeD. Available at: www.statistikbanken.dk. Accessed 2004.
30. van Hout BA. Discounting costs and effects: A reconsideration. Health Econ. 1998;7:581-594.
31. van Hout BA, Simoons ML. Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat? Eur Heart J. 2001;22:751-761.
32. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326:1419.
33. Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med. 2002;162:2197-2202.